What is SRY (sex‑determining region Y) testing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is SRY Testing?

SRY testing is a molecular genetic test that detects and analyzes the Sex-determining Region Y (SRY) gene, which is the master switch gene on the Y chromosome responsible for initiating male sex development and testis formation.

Purpose and Clinical Applications

SRY testing serves several critical diagnostic functions in evaluating disorders of sex development (DSD):

  • Detecting Y-chromosomal material in patients with ambiguous genitalia or discordant sexual development 1
  • Identifying mutations in the SRY gene that cause sex reversal, particularly in 46,XY individuals with female phenotype or gonadal dysgenesis 2, 3
  • Assessing cancer risk in DSD patients, as Y-chromosomal material (particularly the GBY region) increases risk of gonadoblastoma and germ cell tumors 4

Testing Methodology

The standard approach combines two complementary techniques:

PCR Amplification and Sequencing

  • PCR amplifies the SRY gene region (typically producing a 648 base pair band) 5
  • Direct DNA sequencing analyzes the entire coding region, with particular focus on the HMG box domain 2, 3
  • Next-generation (deep) sequencing can be used for mosaic karyotypes to detect low-level mutations 4

FISH Validation (When Applicable)

When using FISH probes for Y-chromosome detection, technical standards require 6:

  • Minimum of 5 metaphase cells scored to verify probe localization
  • Male cells should be used to exclude cross-hybridization with Y chromosome loci
  • Probe sensitivity of at least 95% for clinical testing
  • Analysis of at least 40 chromosomes for sex chromosome targets

Key Clinical Findings

Mutations are found in approximately 10-15% of 46,XY individuals with complete gonadal dysgenesis 2, 3. The majority of pathogenic mutations cluster in the HMG box domain, which is responsible for DNA binding and contains nuclear localization signals 4, 7.

Important Caveats:

  • Higher mutation rate in complete vs. partial gonadal dysgenesis: Patients with complete gonadal dysgenesis show higher prevalence of SRY mutations than those with partial dysgenesis 3
  • Rare in mosaic DSD: SRY mutations are uncommon in patients with mosaic karyotypes like 45,X/46,XY, suggesting other mechanisms drive gonadal maldevelopment in these cases 4
  • Familial mutations exist: Some SRY mutations show variable penetrance, with affected families containing both fertile males and sex-reversed females 2, 7
  • Negative results don't exclude diagnosis: The relatively low mutation frequency means most XY sex reversal cases involve other genetic factors or undiscovered SRY regulatory regions 2

Practical Testing Algorithm

When to order SRY testing 1:

  1. Any child/adolescent with ambiguous genitalia
  2. 46,XY karyotype with female phenotype or undervirilization
  3. Turner syndrome variants to assess Y-chromosomal material and cancer risk
  4. Discordance between chromosomal sex and phenotypic sex

Combine with karyotype analysis: SRY gene detection provides rapid molecular confirmation but should be paired with G-banding karyotype analysis to identify structural Y chromosome abnormalities (deletions, additions, ring chromosomes) that may not be apparent from gene sequencing alone 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.